FY2027 Earnings Estimate for Q32 Bio Issued By HC Wainwright

Q32 Bio Inc. (NASDAQ:QTTB) – Equities researchers at HC Wainwright boosted their FY2027 earnings per share (EPS) estimates for Q32 Bio in a research report issued on Wednesday, September 30th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of ($1.54) per share for the year, up from their previous forecast of ($2.00). HC Wainwright has a “Buy” rating and a $36.00 price target on the stock. The consensus estimate for Q32 Bio’s current full-year earnings is ($1.54) per share.

Several other research firms have also recently weighed in on QTTB. Mizuho upgraded shares of Q32 Bio to a “strong-buy” rating in a research report on Monday, September 7th. Jefferies Financial Group initiated coverage on shares of Q32 Bio in a report on Monday. They issued a “buy” rating and a $29.00 price target on the stock. Morgan Stanley initiated coverage on shares of Q32 Bio in a research report on Monday, August 24th. They set an “overweight” rating and a $34.00 price objective on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Q32 Bio in a research report on Wednesday, September 16th. Finally, Oppenheimer reaffirmed an “outperform” rating on shares of Q32 Bio in a report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, Q32 Bio currently has a consensus rating of “Moderate Buy” and a consensus price target of $30.60.

Q32 Bio Trading Down 0.2%

Shares of QTTB opened at $8.25 on Friday. Q32 Bio has a 12-month low of $1.90 and a 12-month high of $23.57. The company has a market cap of $245.60 million, a PE ratio of 2.75 and a beta of 0.31. The stock has a 50-day moving average price of $13.40 and a 200-day moving average price of $10.79.

Q32 Bio (NASDAQ:QTTB) last announced its earnings results on Wednesday, August 5th. The company reported ($0.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.02.

Institutional Trading of Q32 Bio

Several hedge funds have recently added to or reduced their stakes in QTTB. Atlas Venture Life Science Advisors LLC boosted its position in Q32 Bio by 29.9% during the second quarter. Atlas Venture Life Science Advisors LLC now owns 2,717,106 shares of the company’s stock valued at $34,616,000 after buying an additional 625,000 shares during the period. Renaissance Technologies LLC boosted its holdings in Q32 Bio by 107.7% during the 1st quarter. Renaissance Technologies LLC now owns 206,915 shares of the company’s stock valued at $1,328,000 after acquiring an additional 107,315 shares during the period. BlackRock Inc. purchased a new stake in Q32 Bio during the 2nd quarter valued at about $1,510,000. Carlyle Group Inc. bought a new position in Q32 Bio during the 2nd quarter worth approximately $769,000. Finally, ADAR1 Capital Management LLC increased its stake in Q32 Bio by 75.0% in the 1st quarter. ADAR1 Capital Management LLC now owns 35,000 shares of the company’s stock worth $225,000 after purchasing an additional 15,000 shares during the period. 31.32% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, CFO Lee Kalowski sold 3,972 shares of the business’s stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $16.56, for a total value of $65,776.32. Following the completion of the sale, the chief financial officer directly owned 138,471 shares in the company, valued at approximately $2,293,079.76. The trade was a 2.79% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Jodie Morrison sold 9,845 shares of the business’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $16.56, for a total transaction of $163,033.20. Following the completion of the sale, the chief executive officer owned 343,259 shares of the company’s stock, valued at approximately $5,684,369.04. The trade was a 2.79% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 16,615 shares of company stock valued at $275,144 over the last quarter. 34.46% of the stock is owned by corporate insiders.

About Q32 Bio

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing therapies for diseases associated with immune dysregulation. The company’s research is aimed at restoring balance in the immune system by targeting biological pathways involved in inflammation, tissue repair and immune regulation.

Q32 Bio’s lead product candidate is bempikibart, also known as ADX-914, a fully human monoclonal antibody designed to inhibit activin A signaling through the activin receptor type IIB pathway.